Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

blinatumomab

View Patient Information
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B lymphocytes.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19 x anti-CD3 bispecific monoclonal antibody
anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103
bispecific T-cell engager MT103
US brand name:Blincyto
Code name:AMG 103
MEDI-538
MEDI538
MT-103
MT103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search